AMAG Pharmaceuticals Inc

AMAG Pharmaceuticals — J.P. Morgan Healthcare Conference 2012

25 slides from AMAG Pharmaceuticals's conference presentation, Jan 9, 2012

  1. Slide 1: AMAG Pharmaceuticals J.P. Morgan Healthcare Conference January 2012

    Slide 1: AMAG Pharmaceuticals J.P. Morgan Healthcare Conference January 2012

    AMAG Pharmaceuticals 1 J.P. Morgan Healthcare Conference January 2012

  2. Slide 2: Forward Looking Statements

    Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein which do not describe historical facts, including but not limited to, stateme

  3. Slide 3: AMAG Overview

    Slide 3: AMAG Overview

    AMAG Overview Marketed Product›Feraheme® (ferumoxytol) Injection for intravenous (IV) use, an IV iron replacement therapy Approved in the U.S. and Canada, and indicated for adult patients with all stages of chronic kidney disease (CKD) with iron deficiency anemia (IDA) Composition of matter patent;

  4. Slide 4: Strong Business Fundamentals

    Slide 4: Strong Business Fundamentals

    Strong Business Fundamentals 4 Specialty Product with Long Patent Life Generating ~$50 million in Annual Revenues Significant Incremental Sales Potential from Geographic and Label Expansion Large Addressable Market Strong Ex-U.S. Partnerships Well-Established U.S. Specialty Sales and Marketing Organ

  5. Slide 5: AMAG: A Review of 2011

    Slide 5: AMAG: A Review of 2011

    3Q11: FDA harmonizes most IV iron labels to contain 30-minute observation periods post-dosing Proposed merger with Allos did not receive the required votes by AMAG stockholders 1Q11: CMS implements bundle for dialysis patients; erodes significant portion of AMAG revenue AMAG sales force realigned to

  6. Slide 6: Market Opportunity & Commercial Progress

    Slide 6: Market Opportunity & Commercial Progress

    Market Opportunity & Commercial Progress 6

  7. Slide 7: Feraheme is Well Positioned

    Slide 7: Feraheme is Well Positioned

    Dosing1 Feraheme Many Other IV Irons Schedule 2 x 510 mg 5-10 x 100–200 mg Delivery Rapid IV Injection (under 1 minute) Slow push or 15-60 minute infusion Observation Period 30 minutes post dosing2 30 minutes post dosing2 Regimen (1 g) 2 treatments within one week 5-10 treatments within one month On

  8. Slide 8: 2.4 Million Adults with Diagnosis of IDA

    Slide 8: 2.4 Million Adults with Diagnosis of IDA

    2.4 Million Adults with Diagnosis of IDA Between 200,000 and 250,000 are Treated with IV Iron4 U.S. Census U.S. Renal Data System, USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Dia

  9. Slide 9: IV Iron Therapy Use in Non-Dialysis Rapidly Growing in U.S.

    Slide 9: IV Iron Therapy Use in Non-Dialysis Rapidly Growing in U.S.

    9 IV Iron Therapy Use in Non-Dialysis IDA treatment is Rapidly Growing in U.S. -Results based on IMS Monthly Data, IMS Weekly Data and Wholesaler Shipment Data. Total IV Iron Grams CAGR: 9.1%

  10. Slide 10: 2010 Non-Dialysis CKD IV Iron Market in the U.S.

    Slide 10: 2010 Non-Dialysis CKD IV Iron Market in the U.S.

    Source: IMS Health DDD Data MAT Dec10 and AMAG company estimates. ~750,000 Grams of IV Iron Used Outside of Dialysis in 2010 in U.S. IV Iron Grams ~50% of Non-Dialysis market estimated to be CKD patients 2010 Non-Dialysis CKD IV Iron Market in the U.S. Current Focus 10 ~$190 million U.S. CKD market

  11. Slide 11: Feraheme — Strong Momentum in Non-Dialysis CKD Market

    Slide 11: Feraheme — Strong Momentum in Non-Dialysis CKD Market

    11 Feraheme — Strong Momentum in Non-Dialysis CKD Market -Results based on IMS Monthly Data, IMS Weekly Data and Wholesaler Shipment Data. Feraheme Grams ~40% Growth in Feraheme Provider Demand from 2010 - 2011

  12. Slide 12: Feraheme Non-Dialysis CKD Provider Demand

    Slide 12: Feraheme Non-Dialysis CKD Provider Demand

    Feraheme Non-Dialysis CKD Provider Demand 12 Feraheme Grams -Results based on IMS Monthly Data, IMS Weekly Data and Wholesaler Shipment Data.

  13. Slide 13: 2012 Key Commercial Imperatives

    Slide 13: 2012 Key Commercial Imperatives

    Enhance commercial leadership at AMAG Hired VP of commercial operations in January 2012 Hired VP of commercial analytics in January 2012 Optimize Feraheme’s pricing strategy Minimize opportunistic discounting Stabilize Feraheme ASP Grow Feraheme CKD IDA Market Share Hematology/Oncology Maintain exis

  14. Slide 14: Growth Opportunities

    Slide 14: Growth Opportunities

    Growth Opportunities 14

  15. Slide 15: Strong Partnerships

    Slide 15: Strong Partnerships

    collaboration in place for EU and numerous ex-U.S. territories Takeda is a leading specialty pharmaceutical company with significant commercial capabilities AMAG leads clinical development activities in the licensed territories and regulatory filings in EU Takeda leads regulatory filings in all othe

  16. Slide 16: Ex-US CKD IDA Expansion of Feraheme

    Slide 16: Ex-US CKD IDA Expansion of Feraheme

    Canadian regulatory approval was granted in December 2011 Feraheme is expected to be launched in Canada in 2012 Marketing Authorization Application is under review by the European Medicines Agency AMAG recently requested, and was granted, a 60-day extension to the filing timeline in order to fully r

  17. Slide 17: Pursuing Broad IDA Label

    Slide 17: Pursuing Broad IDA Label

    Global phase III registrational program for Feraheme in patients with IDA, regardless of the underlying cause, 98% enrolled Phase III, double-blind, placebo-controlled trial Primary endpoint: mean change in hemoglobin from Baseline to Week 5 [Day 35] Target enrollment: 800 patients; enrollment neari

  18. Slide 18: Non-CKD IDA Represents a Large Underserved Market

    Slide 18: Non-CKD IDA Represents a Large Underserved Market

    Non-CKD IDA Represents a Large Underserved Market Estimated opportunity is nearly 4.5 million patients; approximately 5% or which are currently treated with IV iron1 Increasing IV iron treatment rates could significantly expand the market opportunity Iron dextrans are the only IV irons with an FDA-a

  19. Slide 19: Expanded Market Opportunity from Broad IDA Label

    Slide 19: Expanded Market Opportunity from Broad IDA Label

    Source: IMS Health DDD Data MAT Dec10 and AMAG company estimates. IV Iron Grams ~$190 million current U.S. CKD market opportunity assuming $500/gram ~$375 million current U.S. CKD and IDA market opportunity assuming $500/gram CKD1 CKD1 IDA Treated Today1 CKD1 IDA Potential1 ~$550 million potential U

  20. Slide 20: Broad IDA Program — Next Steps

    Slide 20: Broad IDA Program — Next Steps

    Expect to complete enrollment in 1Q2012 R&D investment in program winds down in 2012 U.S. sNDA filing targeted for 2H2012 Determining commercialization strategy for various specialties (Gastro, Oncology, OB/GYN) Potential broad IDA approval in EU would result in a significant milestone payment from

  21. Slide 21: Financial Overview

    Slide 21: Financial Overview

    Financial Overview 21

  22. Slide 22: 4Q2011 Expected Results

    Slide 22: 4Q2011 Expected Results

    Total revenues of $14.3 - $15 million, including between $12.4 - $13.1 of net Feraheme product revenues ~24,250 grams of provider demand ~600 gram increase in inventory held at wholesalers/ distributers Gross-to-net adjustment expected for quarter of 32% - 35% Total operating expenses of between $38

  23. Slide 23: 2012 Milestones and Financial Outlook

    Slide 23: 2012 Milestones and Financial Outlook

    2012 Milestones and Financial Outlook Clinical and regulatory milestones Complete enrollment of broad IDA phase 3 registration program Regulatory decisions in international markets on CKD filings Present/publish IDA program data Submit sNDA in US for broad IDA indication Commercial and business mile

  24. Slide 24: Leveraging Core Assets to Create Long-term Stockholder Value

    Slide 24: Leveraging Core Assets to Create Long-term Stockholder Value

    Leveraging Core Assets to Create Long-term Stockholder Value Core Assets Strong balance sheet, with more than $225 million in cash and no debt Talented employee base, with a U.S. commercial footprint, including a sales force, focused on hematology/oncology and hospitals Feraheme, a marketed drug tha

  25. Slide 25: AMAG Pharmaceuticals Investor Relations Contact

    Slide 25: AMAG Pharmaceuticals Investor Relations Contact

    AMAG Pharmaceuticals 25 INVESTOR RELATIONS CONTACT: 617-498-3303

Source: SEC EDGAR · 8-K filed Jan 9, 2012

More decks from AMAG Pharmaceuticals Inc